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Abstract
Cysteine rhenium colloid (CRC) requires less medical isotope than standard sulfur colloid (SC) for sentinel
lymph node biopsy (SNB). Our retrospective cohort study on 1205 consecutive early, clinically node-negative
breast cancer patients who underwent SNB with either isotope suggests CRC is an alternative to SC in
detecting sentinel lymph nodes, and uses less medical isotope.
Background: Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical
shortage. Our center uses a modiﬁcation of the standard SC, called CRC, that has been shown to require less medical
isotope for the same procedure. Our objective was to determine if there was a signiﬁcant difference between SC and
CRC in successful lymph node identiﬁcation in breast cancer patients. Patients and Methods: This was a retro-
spective cohort study using prospectively-collected data on 1205 consecutive early, clinically node-negative breast
cancer patients who underwent a SNB between 2002 and 2008 at 2 tertiary hospitals in Canada. Results: There was
no difference in successful lymph node identiﬁcation rate (P ¼ .50) or in the mean number of positive nodes identiﬁed
between the 2 colloids (P ¼ .88). The CRC group had a signiﬁcantly lower rate of delayed adverse events (4.91% vs.
0.59%, P < .0001) even after adjusting for whether axillary dissection occurred on the same day as the biopsy
(adjusted odds ratio, 0.12; 95% conﬁdence interval, 0.04-0.40; P ¼ .001). Conclusion: Our ﬁndings suggest that there
is no signiﬁcant difference between CRC and SC in detecting sentinel nodes; however, CRC uses less medical iso-
topes. In the current climate of critical shortages of medical radioisotopes, radiocolloids should be selected for use
based on amount of radioisotope required.
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Breast cancer is the most common noncutaneous cancer in
women, and the most powerful prognostic factor of survival is
regional lymph node status.1 Thus, it is important to identify
patients with nodal involvement to differentiate those that will
clearly beneﬁt from further treatments and staging. Sentinel lymph
node (SLN) biopsy (SNB) has largely supplanted axillary dissection
as a staging procedure because it reduces surgical morbidity and*This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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sentinel nodes during SNB is guided by preoperative sentinel node
lymphoscintigraphy (SL) and application of blue dye.2 SL uses
scintigraphic visualization of lymphatic drainage of a speciﬁc tumor
site after injection of a radiolabeled colloid. The current standard in
Canada for this procedure is technetium-99m (Tc-99m) sulfur
colloid (SC). Typically, the SC used for SL requires a ﬁltration step
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Table 1 Comparison of Groups
Variable
Cysteine
Rhenium Colloid Sulfur Colloid P
N 603 602
Age 57.48 (SD, 12.05) 59.56 (SD, 12.40) .003
Successful
Identiﬁcation of
Sentinel Nodes
597 (99.17%) 600 (99.50%) .50
Mean Sentinel
Nodes Identiﬁed, n
2.06 (SD, 1.41) 2.71 (SD, 1.57) <.0001
Total Positive
Nodes, n
170 (13.20%) 138 (8.41%) <.0001
Blue Dye Used 581 (99.15%) 594 (99.66%) .28
Intraoperative
Adverse Event
0 (0.00%) 1 (0.17%) 1.00
Delayed Adverse
Event
3 (0.59%) 26 (4.91%) <.0001
Sentinel Nodes
Identiﬁed Using
Tc-99
585 (97.34%) 574 (96.31%) .31
Sentinel Nodes
Identiﬁed Using
Blue Dye
522 (86.86%) 513 (86.07%) .69
Axillary Dissection 124 (20.56%) 115 (19.10%) .52
Same Day Axillary
Dissection
32 (25.81%)a 93 (80.87%)a <.0001
aPercentage of all who had axillary dissection.
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ﬁltration step can also increase cost, time, and radiation exposure to
health care professionals. SL is listed as a top priority study in the
dissemination of medical isotopes during times of critical shortages.
A member of our group (PLZ) developed a modiﬁcation of SC,
called cysteine rhenium colloid (CRC), which has the optimal size
range for breast cancer SL such that the ﬁltration is avoided and
waste is reduced. Thus, SL using Tc-99m CRC uses the same
clinical methodology and requires 70% to 90% less technetium
than ﬁltered SC.4-6 In pilot trials, Tc-99m CRC successfully
found the sentinel node in 98% of patients, which compared
favorably to a 94% success rate using blue dye in breast cancer
patients.7,8 Our objective was to determine if there was a
signiﬁcant difference between the standard SC and CRC SL in
successful lymph node identiﬁcation in breast cancer patients. As
secondary objectives, we also were interested in determining the
mean number of lymph nodes identiﬁed, the metastatic status of
the nodes on pathology, and adverse advents (either intraoperative
or delayed).
Patients and Methods
A retrospective cohort design was used. No center uses both
products on a regular basis for this indication. Thus, a comparison
of cohorts at 2 Canadian tertiary care hospitals was undertaken:
London Health Sciences Centre (LHSC), which used CRC, and
Sunnybrook Health Sciences Centre (SHSC), which used SC. The
anticipated percentage of lymph node identiﬁcation was estimated
as 96% based on literature reports. The sample size calculation was
conducted using a 2-sided comparison of proportions, allowing for
power to detect a 4% difference between for Tc-99 CRC and the
standard Tc-99m SC (b ¼ 0.20; a ¼ 0.05).9 The calculated
sample size was 1200. Ontario Cancer Research Ethics Board and
institutional research ethics board approvals were obtained.
Deidentiﬁed data were obtained from the charts for 602 (SHSC)
and 603 (LHSC) consecutive early, clinically node-negative breast
cancer patients who underwent SNB between 2002 and 2008.
Patients with T1 or T2 tumors who were clinically node-negative
were included in the study. Patients were excluded if they had
neoadjuvant therapy. The lymphoscintigraphy report, operative
note, postoperative note, and pathology report were obtained. Using
the individual-level data from these deidentiﬁed reports, each
patient was evaluated for: successful lymph node identiﬁcation
(primary outcome) and a number of secondary outcomes including
any adverse events (either intraoperative from the operative report or
delayed as described in the postoperative/clinic notes), the mean
number of lymph nodes identiﬁed, and the metastatic status of these
nodes based on the pathology reports. Delayed adverse events were
deﬁned as complications (eg, wound infection, hematoma, seroma)
related to SNB that required medical assessment/intervention and
were reported within 30 days after the procedure. Data abstraction
was completed by the same trained abstractor with regular consis-
tency checks. Continuous data were assessed using independent
samples t tests with Wilcoxon rank sum test being applied in cases
of nonnormal distribution. Categorical data were assessed using
Fisher exact test. Multivariable logistic regression was used for
adjusted analyses. Results from this study were analyzed using SPSS/
PASW v20 statistical software (SAS).Clinical Breast Cancer February 2015Technical Aspects of CRC
The Tc-99m CRC was developed and compared with many other
colloidal products for size range, radiochemical purity, stability,
optimal formulation, intravenous biokinetics in mice, and for
lymphatic migration from intradermal foot injection in rabbits.4-6
CRC has a mean size of 10 nm to 12 nm based on electron micro-
scopy.4-6 Using ﬁlter retention testing, > 90% of the radioactive
colloid is retained on a 0.22 mm ﬁlter.4-6 The smaller size of Tc-99m
CRC optimizes it for clinical use in SL because it concentrates in the
sentinel node and shows minimal leakage to nonsentinel nodes.6
Two pilot human clinical trials were completed in melanoma and
breast cancer lymphatic staging.7,8 The sterile compounding
methods and extensive quality control methods were those previously
used with our own SC preparation licensed with Health Canada.
Results
The SC group was older than the CRC group with a statistically
signiﬁcant mean age difference of 2 years (P ¼ .003) (Table 1). Of
the 602 patients in the SC group, 600 (99.5%) had successful
identiﬁcation of SLNs and 597 (99.17%) of the 603 of the CRC
group had successful identiﬁcation; there was no signiﬁcant differ-
ence in successful identiﬁcation rate (P ¼ .50). There was a
signiﬁcantly greater mean number of SLNs identiﬁed in the SC
group (2.71 vs. 2.06; P < .0001); the median number of nodes
identiﬁed was 2 for both with interquartile ranges of 1 to 3 and 2 to
4 nodes for the CRC and SC groups, respectively. In contrast, the
total number of positive nodes identiﬁed (deﬁned by histology) was
signiﬁcantly greater in the CRC group (170 (28%) vs. 138 (23%);
P < .0001). Furthermore, the CRC group had a signiﬁcantly
greater proportion of positive nodes in the ﬁrst 2 SLNs (P ¼ .004
Figure 1 Percentage of Patients Stratiﬁed According to Number of Lymph Nodes Identiﬁed. *P [ .02; **P < .0001
Abbreviations: CRC ¼ Cysteine Rhenium Colloid; SC ¼ Sulfur Colloid.
Biniam Kidane et aland P ¼ .046) (Figure 1, Table 2). There was no signiﬁcant dif-
ference in proportion of positive nodes after the second SLN
(Figure 1, Table 2). There was no difference in mean number of
positive nodes between the 2 groups (P ¼ .88). There was no dif-
ference between groups in frequency of blue dye use (P ¼ .28) or in
detection rate of SLNs using either the blue dye method (P ¼ .31)
or scintigraphy (P ¼ .69). There was no difference in progression to
axillary lymph node dissection (ALND) rates (P ¼ .52). However,
the SC group had a signiﬁcantly greater rate of same-day ALND.
Although there was no difference in rates of intraoperative adverse
events, the CRC group had a signiﬁcantly lower rate of delayed
adverse events (0.59% vs. 4.91%; P < .0001). The CRC group had
a signiﬁcantly lower rate of delayed adverse events even after
adjusting for same-day ALND (adjusted odds ratio, 0.12; 95%
conﬁdence interval [CI], 0.04-0.40; P ¼ .001).
Discussion
Overall, our ﬁndings suggest that CRC is not signiﬁcantly
different from SC in successful identiﬁcation of SLNs. AlthoughTable 2 Sentinel Lymph Node Pathology
Sentinel
Lymph Node
Cysteine Rhenium Colloid S
Positive Negative Positive
1 118 483 80
2 37 322 30
3 10 156 15
4 3 68 8
5 2 43 2
6 0 26 1
7 0 13 1
8 0 7 1
9 0 4 0
For each identiﬁed sentinel node, the number of patients in whom pathological analysis revealed positiv
odds of identifying positive nodes with cysteine rhemium colloid compared with the odds of identifythere was a signiﬁcantly greater mean number of SLNs identiﬁed in
the SC group, the total number of positive nodes was signiﬁcantly
greater in the CRC group, supporting earlier preclinical data that
showed less migration of CRC to nonsentinel nodes compared with
SC.4,7 Moreover, histological examination showed that the CRC
group had a signiﬁcantly greater proportion of positive nodes in the
ﬁrst 2 SLNs but not in subsequent SLNs. A potential explanation
for this discrepancy might be that there might have been differences
in the distribution of tumor size/stage between groups or differences
in pathological examination techniques, but this information was
not captured in our data extraction. In the end, there was no
signiﬁcant difference between the 2 groups in mean number of
positive nodes identiﬁed. Thus, CRC seems equivalent and perhaps
better able to identify sentinel nodes without requiring the resection
of additional nodes (ie, which did not contribute to clinical nodal
staging), as seen with SC.
There was a signiﬁcantly lower rate of delayed adverse events and
of same-day ALND in the CRC group. However, the latter ﬁnding
was related to the routine practice at the hospital using SC, whereulfur Colloid
Odds Ratio
(95% CI) PNegative
516 1.58 (1.16-2.15) .004
434 1.66 (1.01-2.75) .046
276 1.18 (0.52-2.69) .70
153 0.84 (0.22-3.28) .81
64 1.49 (0.20-10.97) .70
35 0.97 (0.92-1.03) 1.00
17 0.94 (0.84-1.06) 1.00
7 0.87 (0.67-1.14) 1.00
5 Not estimable
e (presence of disease) and negative (no disease) disease is shown. The odds ratio describes the
ing positive nodes with sulfur colloid for each sentinel node.
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e44 -surgeons perform intraoperative frozen sections and proceed to
same-day ALND if positive. The higher incidence of delayed
adverse events in the SC group was speciﬁcally related to the SNB
and not inﬂated because of adverse events related to same-day
ALND: the CRC group had a signiﬁcantly lower rate of delayed
adverse events even after adjusting for same-day ALND (adjusted
odds ratio, 0.12; 95% CI, 0.04-0.40; P ¼ .001). It is recognized
that these data are collected retrospectively and as such, differences
in delayed adverse events might be differentially captured and
recorded by the 2 institutions, which could account for this
difference.
Previous studies have reported the radiopharmaceutical quality
and stability of CRC, and its efﬁcacy in detection of SLNs.4-9 It has
not previously been compared clinically with the standard SC in the
setting of breast cancer. Because of the infrastructure barriers of
carrying out a fully randomized single-center prospective compari-
son of CRC and SC, a comparison of 2 contemporaneous cohorts at
2 different centers was undertaken. Because the 2 cohorts being
compared were at different sites, variation in established methods
beyond the difference in colloid used were unavoidable. Further-
more, breast cancer care requires a coordinated multidisciplinary
team approach (including, but not limited to, surgeons, radiologist,
oncologists, and pathologists); it is possible that any differences
detected in SLN identiﬁcation rates and adverse events are more
related to the differences between the 2 teams at the 2 different
hospitals rather than the 2 different colloids used. In a review of
SLN biopsy methodology in breast cancer, Bonnema and van de
Velde concluded that SLN biopsy is a generally robust procedure
despite large variations in isotope technique (ie, choice and dosage
of isotope, carrier, particle size, timing of injection, and deﬁnition of
a successful result).2 That being said, we discuss these differences
and the potential effect on our conclusions below.
The ﬁrst difference between the 2 cohorts in this study was in
radiocolloid injection technique. Evidence shows that periareolar
injection yields the best detection rates and is thus the technique
advocated by Canadian guidelines and others.10 Periareolar injec-
tion was used in CRC and SC. However, in the CRC group,
intradermal periareolar injection was used and in the SC group
subdermal (subcutaneous) periareolar injection at 4 quadrants was
used. Both injection sites target the subdermal lymphatic plexus and
thus should have the same drainage pattern, explaining why most
studies have grouped both injection methods together.10 More
recently, a study demonstrated no difference in SLN identiﬁcation
rate using either injection method.11
In general, there is variability among centers that use SC in the
practice of ﬁltration, which is where up to 90% of Tc-99m is lost on
the ﬁlter.6 Some centers use ﬁltered SC (usually through a 0.22-mm
ﬁlter to obtain the ideal colloid particle size to be trapped within the
SLN) and others use unﬁltered SC, presumably in an effort to avoid
loss of signiﬁcant amounts of radiocolloid, and instead increase the
dose injected to compensate for particle size limitations. The liter-
ature is somewhat divided on which technique is better. Some
studies suggest that ﬁltered SC results in higher yield of SLNs and
secondary nodes.3,12 Conversely, other studies found that unﬁltered
SC is superior and suggest that the ﬁltration allows the smaller SC
particles to spread extensively, essentially causing signal washout and
making it more difﬁcult to localize true SLNs.13 In the end, evenClinical Breast Cancer February 2015studies supportive of ﬁltration point out that it is unclear whether
the higher detection rates in those studies is due to increased
detection of true SLNs or whether the detection rate is inﬂated by
increased detection of nonsentinel secondary/tertiary nodes caused
by increased migration of smaller particles to non-SLNs because of
limited trapping. In the SC group in our study unﬁltered SC was
used. Thus, higher dose and volume of Tc-99m were required
compared with the CRC group. The present study did not compare
CRC and ﬁltered SC; ﬁltration might result in an equivalent use of
volume, but would waste signiﬁcant amounts of isotope and
increase cost, time, and radiation exposure to the health care
professional. For these reasons, CRC might be more advantageous
than ﬁltered SC.
The literature suggests that 85% to 99% of all positive nodes are
found in the ﬁrst 2 SLNs.14 Furthermore, several studies have found
increased postoperative complication rates, operating room time/
cost, and pathology costs when more than 3 or 4 SLNs are
removed.14,15 Our ﬁndings are consistent with the literature that if
positive nodes existed, they were found within the ﬁrst 2 SLNs.
Furthermore, our ﬁnding that the SC group had signiﬁcantly greater
rates of delayed adverse events might have been a consequence of
the greater mean number of SLNs removed, as suggested by the
literature.14,15
Technetium-99 SC is the only commercially available product
available in Canada. Nanocolloid human serum albumin
(Nanocoll) and antimony trisulphide colloid are mainly used in
Europe.16 Tc-99m Lymphoseek, a mannose-based colloid, was
recently approved in the United States, after our study was
completed.17 Although promising, the studies supporting the use
of this new radiocolloid were criticized because they only
compared detection rates between Lymphoseek and blue dye
rather than another radiocolloid. Comparison of Tc-99m ﬁltered
SC, Tc-99m unﬁltered SC, Tc-99m antimony trisulphide colloid
and Tc-99m CRC in a rabbit model, showed that all colloids
migrated to the ﬁrst draining lymph node but that CRC had the
highest entrapment in the ﬁrst lymph node, so that there was less
relative leakage past the sentinel node.5,6 Nanocoll is not licensed
in North America and was not available for comparison during
this initial development of the Tc-99m CRC. There is a paucity
of clinical human studies comparing the different radiocolloids
head-to-head, thus, evidence on the comparative efﬁcacy of each
radiocolloid is limited. Cost comparisons are also challenging to
make because of the extra factors that contribute to the ﬁnal cost
for a sentinel lymphoscintigraphy procedure. The Tc-99m CRC
is not yet commercially available but would likely have a pricing
similar to the only other commercially available product in North
America, Tc-99m SC. At our center, current daily reagent costs
to produce Tc-99m SC average approximately $100 USD, with
cost per patient varying depending on the number of patients
booked per day and the timing between injection and procedure,
to correct for the 6-hour half-life. Additional costs of manpower
and ﬁlters would increase the costs by approximately $25 USD
per vial with a slightly increased radiation exposure for the
technologist. Thus, using these ﬁgures, one could estimate a
potential cost savings of up to $25 USD per vial with use of CRC
compared with SC. Ultimately, however, costs are likely similar
between different colloids and pricing differences can be
Biniam Kidane et alinﬂuenced more by regional contracts than by true cost differ-
ences. In the end, we believe that the true decision about which
colloids to use should be driven instead by those that use the least
amount of technetium because of its scarce availability
worldwide.
Retrospective analyses, carry with them an inherent risk of bias.
Because we did not capture exact tumor size and histologic tumor
phenotype in the data abstraction, there may be differences in the
distribution of these factors between groups that might have biased
our ﬁndings. This study was not randomized and the 2 groups
being compared were at 2 different sites with 2 different sets of
protocols. Thus, there is a risk that our ﬁndings were due to or
inﬂuenced by unidentiﬁed confounding variables. That being said,
there was no signiﬁcant difference between groups in use of blue
dye, successful identiﬁcation of SLNs using blue dye, intra-
operative adverse events, or ALND rates. Future studies should
include a prospective, randomized and blinded comparison
between the 2 colloids within the same center. A cost effectiveness
analysis could then be undertaken.
Conclusion
Our ﬁndings suggest that CRC is not signiﬁcantly different
from SC in demonstrating very high rates of successful identiﬁ-
cation of SLNs. CRC seems better able to identify positive lymph
nodes within the ﬁrst 2 to 3 SLNs compared with SC. Our
ﬁndings show that CRC requires lower volumes and radiation
doses to effect similar detection rates in SLN procedures done for
breast cancer staging. Preliminary clinical trials have shown CRC
to be just as effective as ﬁltered SC and requires 70% to 90% less
technetium.4,7,9 Although the control group in this study used
unﬁltered SC and thus did not waste 70% to 90% of the tech-
netium through ﬁltration, they did use much higher radioisotope
volumes and radiation doses. Finding ways to minimize use of
medical isotopes is a critical step in overcoming the recurrent
medical isotope shortages on a global basis. Our ﬁndings suggest
that CRC appears to be a viable alternative to SC in detecting
SLNs. Prospective, randomized controlled studies are required to
validate the present study.
Clinical Practice Points
 Sentinel node lymphoscintigraphy with Tc-99m SC is
commonly used. Medical isotopes such as this are repeatedly in
critical shortage globally, and sustainable use is prudent to ensure
their availability.
 Cysteine rhenium colloid appears to be as effective as SC in
detecting SLNs. Furthermore, it seems better able to identify
positive lymph nodes within the ﬁrst 2 to 3 SLNs and has
signiﬁcantly lower rates of delayed adverse events compared with
SC. These ﬁndings contribute to evidence that CRC might be a
viable alternative to SC and has the added beneﬁt of using less
medical isotope. The present study might lead to further
randomized studies comparing the 2 isotopes head-to-head,
which might eventually lead to a change in clinical practice.Acknowledgments
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